Perrigo (PRGO) CFO awarded 52,678 RSUs, now holds 77,760 ordinary shares
Perrigo Company plc's EVP & Chief Financial Officer, Eduardo Guarita Bezerra, was granted 52,678 Restricted Stock Units (RSUs) that will vest in three equal annual installments starting May 13, 2027. Following this grant, Mr. Bezerra now directly holds 77,760 ordinary shares and the newly awarded 52,678 RSUs. This equity compensation aligns his interests with the company's share performance over time.
Perrigo (NYSE: PRGO) director logs RSU grant, vesting and tax share disposition
Perrigo Company plc director Jonas Samuelson reported equity activity including receiving 16,681 Restricted Stock Units (RSUs) on May 13, 2026, which are set to vest on May 13, 2027. On May 14, 2026, 7,305 RSUs vested and converted into ordinary shares, and 3,507 ordinary shares were disposed of at $10.84 each to cover tax obligations. Following these transactions, Samuelson directly owns 5,392 ordinary shares, with the newly granted RSUs still outstanding.
Perrigo (PRGO) director reports RSU grant, exercise and tax-withholding share disposition
Perrigo Company plc director Donal O'Connor reported recent equity compensation activities. He exercised 7,305 Restricted Stock Units (RSUs) and had 3,507 Ordinary Shares withheld at $10.84 per share to cover tax obligations. Additionally, O'Connor received a new grant of 16,681 RSUs, which will vest on May 13, 2027.
Perrigo (PRGO) director reports RSU grant, share conversion and tax withholding
Perrigo Company plc (PRGO) director Kevin Francis Egan reported equity activity including a grant of 16,681 Restricted Stock Units (RSUs) on May 13, 2026. On May 14, 2026, 7,305 RSUs were converted into ordinary shares, and 3,507 ordinary shares were disposed of at $10.84 per share to cover tax obligations. This filing reflects compensation-related equity movements rather than open-market trading.
[Form 4] PERRIGO Co plc Insider Trading Activity
Perrigo Co plc director Geoffrey M. Parker reported insider trading activity detailed in a Form 4 filing. On May 14, 2026, he exercised 7,305 Restricted Stock Units (RSUs) and had 3,507 shares withheld for taxes, bringing his direct holding to 36,217 ordinary shares. He also received a new grant of 16,681 RSUs on May 13, 2026, vesting in May 2027, and holds additional shares indirectly through a Roth IRA and a revocable trust.
Perrigo (NYSE: PRGO) awards 31,607 RSUs to EVP and CSO
Perrigo Company plc (NYSE: PRGO) has awarded 31,607 Restricted Stock Units (RSUs) to Abigail Lennox, EVP and CSO, as reported in a Form 4 SEC filing. These RSUs represent a contingent right to one Perrigo ordinary share each and will vest in three equal annual installments starting May 13, 2027. This grant is part of her equity compensation, bringing her direct holdings to 2,780 ordinary shares plus the potential full acquisition of the RSU shares upon vesting.
Perrigo (NYSE: PRGO) awards EVP 22,388 restricted stock units
Perrigo Company plc (NYSE: PRGO) has awarded 22,388 Restricted Stock Units (RSUs) to Matthew John Winterman, EVP, Supply, Ops, Strategy, as detailed in a recent Form 4 filing. These RSUs represent a contingent right to receive one Perrigo ordinary share each and will vest in three equal annual installments starting May 13, 2027. Following this grant, Winterman's reported holdings include 22,388 RSUs, with no non-derivative securities beneficially owned.
Perrigo (PRGO) director logs RSU grant, vesting and tax share disposition
Perrigo Company plc director Bradley A. Alford reported routine equity compensation activity, including the grant of 16,681 Restricted Stock Units (RSUs) on May 13, 2026. On May 14, 2026, 7,305 RSUs vested and converted into ordinary shares, followed by a disposition of 3,507 shares on May 15, 2026, to cover tax obligations. After these transactions, Alford directly owned 44,958.148 ordinary shares, clarifying that these were tax-related movements rather than open-market sales.
Perrigo (NYSE: PRGO) director granted 16,681 RSUs and exercises 7,305 units
Perrigo Company plc director Albert Manzone reported equity compensation activity, receiving 16,681 Restricted Stock Units (RSUs) on May 13, 2026, which vest on May 13, 2027. On May 14, 2026, he exercised 7,305 RSUs into ordinary shares, with 3,507 shares withheld for tax obligations at $10.84 per share. Following these transactions, Manzone directly holds 16,353 ordinary shares.
Perrigo (NYSE: PRGO) director gains shares through RSU grant and vesting
Perrigo Company plc director Julia M. Brown reported equity compensation activities, including the grant of 16,681 Restricted Stock Units (RSUs) vesting in 2027. Additionally, 7,305 RSUs vested and converted into ordinary shares, with 3,507 shares withheld for tax obligations at $10.84 per share. Following these transactions, she directly holds 11,832 ordinary shares in Perrigo.
Perrigo Co. PLC stock underperforms Friday when compared to competitors
Perrigo Co. PLC's stock (PRGO) fell 2.12% to $10.61 on Friday, marking its third consecutive day of losses. This underperformance occurred during a generally negative trading session, with the S&P 500 Index and Dow Jones Industrial Average also experiencing declines.
Perrigo (PRGO) director Orlando Ashford exercises 10,669 RSUs and withholds 5,122 shares for taxes
Perrigo Company director Orlando D. Ashford engaged in compensation-related share movements, including receiving 24,363 new Restricted Stock Units (RSUs) and converting 10,669 RSUs into ordinary shares at $10.84 each. To cover tax obligations, 5,122 shares were withheld, rather than sold on the open market. Following these transactions, Ashford directly held 27,717 ordinary shares, indicating a net increase in his ownership through equity compensation.
Perrigo Co. PLC stock underperforms Monday when compared to competitors
Perrigo Co. PLC (PRGO) stock declined by 5.47% to $11.07 on Monday, underperforming the broader market, which saw the S&P 500 and Dow Jones Industrial Average both rise by 0.19%. This marks the third consecutive day of losses for the company's shares.
Vanguard Group Inc. Buys 1,101,154 Shares of Perrigo Company plc $PRGO
Vanguard Group Inc. increased its stake in Perrigo Company plc by 7.9% in the fourth quarter, acquiring an additional 1.1 million shares. This brings their total holding to 14.98 million shares, representing about 10.89% of the company. Despite Perrigo reporting Q1 earnings of $0.43 per share that beat estimates, its revenue of $841.8 million fell short and declined 7.2% year over year. The company declared a quarterly dividend of $0.29 per share, resulting in an annualized yield of around 9.9%, while analysts generally hold a "Hold" rating for the stock with a $19.33 target price.
Perrigo Company plc (NYSE:PRGO) Q1 2026 Earnings Call Transcript
Perrigo Company plc (NYSE: PRGO) exceeded Q1 2026 earnings expectations with reported EPS of $0.43 against an expected $0.39, despite facing a challenging market environment, particularly due to softer cough and cold incidence and retailer inventory destocking. The company reaffirmed its 2026 outlook, anticipating results to be weighted towards the second half of the year, driven by stabilizing category consumption, benefits from cost-saving initiatives, and growth drivers. Perrigo also highlighted significant market share gains in U.S. store brand OTC products and progress with its "Three-S" plan to stabilize, streamline, and strengthen the company, including the divestiture of its Dermacosmetics business and ongoing strategic reviews of Infant Formula and Oral Care.
Perrigo Company plc Q1 2026 Earnings Call Summary
Perrigo Company plc reported an 8.3% CORE net sales decline in Q1 2026, primarily due to a challenging market and retailer inventory destocking, but reaffirmed its full-year guidance expecting a strong second-half recovery. The company's 'Three-S' plan has improved U.S. store brand OTC volume share, and strategic initiatives like the Dermacosmetics divestiture and ongoing reviews of Infant Formula and Oral Care aim to streamline its portfolio and reduce debt. Innovation, particularly in nicotine replacement therapy and new Infant Formula offerings, is expected to be the main growth driver in the latter half of the year.
Perrigo Co. PLC stock underperforms Thursday when compared to competitors
Perrigo Co. PLC (PRGO) stock fell 4.40% on Thursday, closing at $11.72. This underperformance occurred on a generally poor day for the stock market, with both the S&P 500 and Dow Jones Industrial Average also declining. The stock's fall ended a two-day winning streak.
Earnings Flash (PRGO) Perrigo Company Plc Reports Q1 Revenue $969.2M, Vs. FactSet Est of $1.04B
Perrigo Company Plc (PRGO) announced its Q1 revenue was $969.2 million, falling short of FactSet's estimate of $1.04 billion. This summary highlights the key financial outcome for the company's first quarter.
Goodwill impairments drive Perrigo (NYSE: PRGO) to deep quarterly loss
Perrigo Company plc (NYSE: PRGO) reported a significant first-quarter loss driven by substantial non-cash goodwill impairments totaling $330.8 million and $75.1 million in restructuring charges. The company's net sales decreased to $969.2 million from $1,043.9 million in the prior year, leading to a net loss of $398.6 million, or $2.87 per diluted share, a sharp decline from a $6.4 million loss in the same period last year. The negative financial performance prompted a strategic review of its infant formula business and an operational enhancement program aimed at streamlining operations and achieving cost savings.
Earnings Flash (PRGO) Perrigo Company Plc Posts Q1 Adjusted EPS $0.43 per Share, Vs. FactSet Est of $0.31
Perrigo Company Plc (PRGO) reported strong first-quarter adjusted EPS of $0.43 per share, significantly surpassing the FactSet estimate of $0.31 per share. This financial performance indicates a better-than-expected quarter for the company.
Perrigo Co. PLC stock outperforms competitors on strong trading day
Perrigo Co. PLC (PRGO) stock rose 5.33% to $12.26, outperforming the S&P 500 Index and Dow Jones Industrial Average on a strong trading day. This marked the stock's second consecutive day of gains. The broad market also saw significant increases, with the S&P 500 up 1.46% and the Dow Jones up 1.24%.
Perrigo to lay off 161 as company heads toward Vermont site closure
Perrigo is laying off 161 employees, approximately 40% of its workforce, at its infant formula production facility in Georgia, Vermont, as "phase one" of the site's complete shutdown. Production is expected to cease by June 30, 2026, with the full closure impacting about 420 staff. The company cited aging infrastructure and evolving regulatory requirements as reasons for the closure, which has drawn disappointment from local officials.
Perrigo Company Releases Q1 2026 Financial Results
Perrigo Company plc (PRGO) announced its Q1 2026 financial results, reporting adjusted earnings of $0.43 per share, significantly exceeding the consensus estimate of $0.32 per share. The company generated $969.2 million in revenue for the quarter, a 7.2% decrease year-over-year, and expects adjusted EPS for FY 2026 to be between $2.00 and $2.30.
Earnings Flash (PRGO) Perrigo Company plc Reports Q1 Revenue $969.2M, vs. FactSet Est of $1.04B
Perrigo Company plc announced its Q1 2026 revenue of $969.2 million, falling short of the FactSet estimate of $1.04 billion. The company also reported adjusted EPS of $0.43 per share, which exceeded the FactSet estimate of $0.31. Perrigo expects its 2026 adjusted EPS to be in the range of $2.00 to $2.30.
Earnings Flash (PRGO) Perrigo Company plc Posts Q1 Adjusted EPS $0.43 per Share, vs. FactSet Est of $0.31
Perrigo Company plc (PRGO) announced its Q1 adjusted EPS of $0.43 per share, surpassing FactSet's estimate of $0.31. This earnings flash was published on May 6, 2026, at 07:17 AM EDT by MT Newswires. The report indicates a positive surprise for the company's first-quarter performance.
Perrigo (NYSE:PRGO) Releases FY 2026 Earnings Guidance
Perrigo (NYSE:PRGO) has updated its FY 2026 earnings guidance, projecting an EPS of $2.25-$2.55, which is notably higher than the consensus estimate of $2.11. The company also forecasted revenues between $4.0 billion and $4.2 billion, aligning closely with analyst expectations. Additionally, Perrigo announced a quarterly dividend of $0.29 per share, translating to an annualized yield of 10.0%.
Perrigo Company plc 2026 Q1 - Results - Earnings Call Presentation (NYSE:PRGO) 2026-05-06
Perrigo Company plc (PRGO) has released its slide deck in conjunction with their Q1 2026 earnings call. The presentation was published on May 6, 2026, and provides details relating to their first-quarter results. This material is made available by Seeking Alpha's transcripts team, which regularly publishes thousands of quarterly earnings calls.
Major goodwill hit drives Perrigo (NYSE: PRGO) Q1 2026 loss as it keeps 2026 EPS outlook
Perrigo Company plc (NYSE: PRGO) reported a significant loss in Q1 2026, primarily due to a $330.8 million non-cash goodwill impairment charge, leading to a reported diluted EPS of $(2.81). Despite the loss and a 7.2% decline in "All In" net sales to $969.2 million, the company maintained its full-year 2026 adjusted EPS outlook between $2.00–$2.30, anticipating a strong second-half recovery. Perrigo also completed the sale of its Dermacosmetics business post-quarter end, securing €305.6 million in upfront cash to be used for debt reduction.
Perrigo Shareholders Endorse Directors, Pay and Capital Flexibility
Perrigo shareholders re-elected all director nominees, approved executive compensation, and ratified Ernst & Young LLP as auditor during their 2026 Annual General Meeting on April 30, 2026. They also backed the company’s 2026 equity plan and renewed the Board’s authority to issue shares under Irish law, reinforcing confidence in the company's governance and financial flexibility. Despite strong shareholder support, Spark, TipRanks’ AI Analyst, rates PRGO as Neutral due to deteriorating profitability and declining revenue, though it notes positive cash generation and reduced balance-sheet leverage.
Perrigo (PRGO) investors back 2026 incentive plan and elect board
Perrigo Company plc shareholders approved the new 2026 Long-Term Incentive Plan at their Annual General Meeting on April 30, 2026, which immediately replaced the 2019 plan. All nominated directors were elected with strong majorities, and shareholders also voted in favor of several other proposals with substantial support. This 8-K filing details the voting results for director elections, auditor ratification, executive compensation, the new incentive plan, and renewal of board authorities under Irish law.
Perrigo earnings ahead: Can cost savings counter portfolio reset? By Investing.com
Perrigo Company PLC is set to release its first-quarter earnings, with analysts expecting 33 cents per share on $1.03 billion revenue, a significant decline from the previous quarter. Investors will be watching how the recent sale of its Dermacosmetics business and a new cost-saving initiative impact future guidance, as 2026 is described as a transition year. The company's restructuring efforts will be key to unlocking value given its current valuation and market challenges.
Perrigo Co. PLC stock underperforms Monday when compared to competitors
Perrigo Co. PLC (PRGO) shares fell by 4.45% to $11.39 on Monday, experiencing an underperformance relative to a broader market downturn where the S&P 500 Index dropped 0.41% and the Dow Jones Industrial Average fell 1.13%. This decline ended a two-day winning streak for the stock.
Perrigo Company (PRGO) Q1 2026 Preview: EPS Est. $0.31, Reports May 6
Wall Street analysts anticipate a challenging Q1 2026 for Perrigo Company (PRGO), with a consensus EPS estimate of $0.31 on revenue of $1.03 billion, reporting May 6. This represents a significant 48.3% year-over-year EPS decline, despite a modest 1.0% decrease in revenue, indicating substantial margin compression. Persistent downward revisions in analyst estimates suggest fundamental business headwinds or revised company guidance.
Perrigo Company plc (NYSE: PRGO) Long Term Investor Alert: Investigation of potential Wrongdoing
A law firm has announced an investigation into potential breaches of fiduciary duties by directors and officers of Perrigo Company plc (NYSE: PRGO) on behalf of current long-term investors. This investigation follows a lawsuit alleging securities laws violations related to Perrigo's acquisition and subsequent management of an infant formula business from Nestlé, which faced significant operational issues, remediation costs, and led to reduced financial outlooks for Perrigo. Investors who hold PRGO shares are encouraged to contact the Shareholders Foundation.
Perrigo completes sale of dermacosmetics unit for €332.6m
Perrigo Company plc has finalized the sale of its branded dermacosmetics business to Karo Healthcare for up to €332.6 million, including €305.6 million upfront and potential future payments. This divestment, which includes brands like ACO and Biodermal, is part of Perrigo's strategy to reduce debt and streamline its portfolio. The company aims to strengthen operations and focus on core categories, with net sales from the divested unit at €120 million in 2025.
Short Interest in Perrigo Company plc (NYSE:PRGO) Drops By 16.6%
Short interest in Perrigo Company plc (NYSE:PRGO) decreased by 16.6% in April, totaling 13,922,505 shares, which represents 10.2% of shares outstanding and a 4.0-day short-interest ratio. Despite missing quarterly EPS estimates, the company declared a $0.29 quarterly dividend, implying a 9.8% annualized yield, and set FY2026 guidance above analyst forecasts. Wall Street analysts currently give Perrigo a "Hold" rating with an average price target of $19.33.
Perrigo gets €306M upfront as it exits ACO, Biodermal, Emolium, Iwostin
Perrigo (NYSE: PRGO) has completed the sale of its branded Dermacosmetics business to Karo Healthcare for up to €332.6 million, including €305.6 million upfront and up to €27.0 million contingent on future sales. The divested unit, which included brands like ACO and Biodermal, generated approximately €120 million in net sales in 2025 and accounted for 5% of Perrigo's adjusted operating income. Perrigo plans to use the net proceeds primarily to reduce debt and strengthen its balance sheet, aligning with its "Three-S" plan to stabilize, streamline, and strengthen the company.
Perrigo completes sale of dermacosmetics unit for €332.6m By Investing.com
Perrigo Company plc has completed the sale of its branded dermacosmetics business to Karo Healthcare for up to €332.6 million, including €305.6 million in upfront cash. The divestment, which includes brands like ACO and Biodermal, is part of Perrigo's strategy to reduce debt and streamline its portfolio. The company plans to use the net proceeds primarily for debt reduction and aims for more consistent and sustainable growth.
Perrigo Completes Divestiture of Dermacosmetics Business
Perrigo Company plc has completed the sale of its branded Dermacosmetics business to Karo Healthcare for up to €332.6 million, including €305.6 million in upfront cash. This divestiture aligns with Perrigo's Three-S plan to Stabilize, Streamline, and Strengthen the Company, allowing them to focus on core categories and reduce debt. The Dermacosmetics business generated approximately €120 million in net sales in calendar year 2025.
Perrigo Co. PLC stock outperforms competitors on strong trading day
Shares of Perrigo Co. PLC (PRGO) gained 4.87% on Thursday, closing at $11.84, outperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also saw gains during the strong trading session. The company's stock, however, is still significantly below its 52-week high.
Perrigo Announces Quarterly Dividend
Perrigo Company plc (NYSE: PRGO) announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, totaling $1.16 per share on an annualized basis. The cash dividend is scheduled for payment on June 16, 2026, to shareholders of record as of May 29, 2026. This announcement highlights Perrigo's commitment to returning value to its shareholders as a leading global provider of consumer products.
Perrigo Announces Quarterly Dividend
Perrigo Company plc announced that its Board of Directors approved a quarterly dividend of $0.29 per share, totaling $1.16 per share annually. This cash dividend is scheduled for payment on June 16, 2026, to shareholders of record as of May 29, 2026. The company is a leading global provider of consumer health products, specializing in over-the-counter self-care solutions.
Perrigo Company plc Announces Quarterly Dividend of $0.29 (NYSE:PRGO)
Perrigo Company plc has declared a quarterly dividend of $0.29 per share, payable on June 5th to shareholders of record on May 29th, resulting in an annualized dividend of $1.16 and a 10.3% yield. The company has a strong dividend history, having increased its dividend for 23 consecutive years, with a payout ratio indicating good coverage by earnings. Despite a recent earnings miss and a negative net margin, analysts expect Perrigo to continue covering its dividend with future earnings.
Perrigo Co. PLC stock underperforms Wednesday when compared to competitors
Perrigo Co. PLC (PRGO) shares fell 1.91% on Wednesday to $11.29, underperforming the broader market which also saw declines in the S&P 500 and Dow Jones Industrial Average. The stock is currently 60.30% below its 52-week high of $28.44 reached on July 25th.
SCHEDULE 13G] PERRIGO Co plc Passive Investment Disclosure (>5%)
Vanguard Capital Management disclosed a 5.27% passive stake in Perrigo Co PLC, holding 7,260,072 shares of common stock as of March 31, 2026. The Schedule 13G filing indicates Vanguard has sole dispositive power over all these shares and sole voting power over 1,050,535 shares. This filing highlights Vanguard's significant, though passive, ownership in the company.
Perrigo declares $0.29 quarterly dividend, payable June 16
Perrigo Company plc (NYSE:PRGO) has declared a quarterly dividend of $0.29 per share, payable on June 16, 2026, to shareholders of record as of May 29, 2026. This dividend, representing a 10.08% yield, marks the 23rd consecutive year the company has raised its dividend. The consumer health company, trading at $11.51, is considered undervalued by InvestingPro, and recently reported fourth-quarter 2025 earnings that slightly missed EPS expectations but exceeded revenue forecasts.
Perrigo Announces Quarterly Dividend
Perrigo Company plc announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, totaling $1.16 per share on an annualized basis. The cash dividend is scheduled for payment on June 16, 2026, to shareholders of record as of May 29, 2026. Perrigo is highlighted as a leading pure-play consumer health company focused on providing high-quality health and wellness solutions, primarily in North America and Europe, through trusted self-care solutions and brands like Opill, Mederma, and Compeed.
Perrigo Announces Quarterly Dividend
Perrigo Company plc announced a quarterly dividend of $0.29 per share, or $1.16 annualized, approved by its Board of Directors. The dividend is payable on June 16, 2026, to shareholders of record on May 29, 2026. This announcement highlights Perrigo's continued commitment to returning value to its shareholders as a leading pure-play consumer health company.
Zacks Research Forecasts Perrigo's Q2 Earnings (NYSE:PRGO)
Zacks Research has increased its Q2 2027 EPS estimate for Perrigo (NYSE:PRGO) to $0.55 and maintained a "Hold" rating on the stock. The company's previous quarter saw an EPS of $0.77, missing consensus estimates, on $1.11 billion in revenue, and it currently offers a quarterly dividend of $0.29. Perrigo's stock opened at $11.53, with a market capitalization of $1.59 billion, and institutional investors hold a significant stake.
Perrigo (NYSE:PRGO) Stock Rating Upgraded by Zacks Research
Zacks Research has upgraded Perrigo (NYSE:PRGO) stock from a "strong sell" to a "hold" rating, issuing updated EPS estimates for Q2 2027, FY2027, Q1 2028, and FY2028. The company recently reported Q1 earnings that missed consensus estimates but revenue exceeded expectations, with analysts maintaining a "Hold" consensus rating and an average price target significantly above the current share price. This upgrade and the analyst consensus suggest potential implied upside for the stock despite recent missed earnings.
